

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED
北京同仁堂國藥有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3613)

**APPOINTMENT OF EXECUTIVE DIRECTOR,
CHIEF EXECUTIVE OFFICER AND
MEMBER OF COMPETITION EXECUTIVE COMMITTEE
AND
RE-DESIGNATION OF ACTING CHIEF EXECUTIVE OFFICER**

**APPOINTMENT OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND
MEMBER OF COMPETITION EXECUTIVE COMMITTEE**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) is pleased to announce that Mr. Wang Chi (“**Mr. Wang**”) has been appointed as an executive director, the chief executive officer and a member of the competition executive committee of the Company with effect from 10 May 2024.

The biographical details of Mr. Wang are set out as follows:

Wang Chi, aged 49, has more than 20 years of experience in medical and pharmaceutical industry. Mr. Wang joined Beijing Tong Ren Tang Pharmaceutical Company Limited* (北京同仁堂製藥有限公司) (“**Pharmaceutical Company**”), a subsidiary of China Beijing Tong Ren Tang Group Co., Ltd., to serve as the general manager, and was appointed as a director of the Pharmaceutical Company in January 2023. Prior to joining Beijing Tong Ren Tang Group, Mr. Wang was the general manager of the Jiangzhong Food Therapy Company Limited and chairman and general manager of subsidiaries and various senior positions in Humanwell Healthcare (Group) Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600079.SH). Mr. Wang attained a bachelor’s degree in Mechanical Manufacture and Design from Department of Mechanical Engineering of Wuhan University (formerly known as Wuhan University of Hydraulic and Electric Engineering) in 1996, and obtained a master’s degree in Business Administration from Economics and Management School of Wuhan University in 2003, and then obtained a Ph.D. in Management from Economics and Management School of Wuhan University in 2011.

Mr. Wang shall hold office until the next following annual general meeting of the Company after his appointment and if re-elected by the shareholders of the Company (the “**Shareholder(s)**”) thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. A service contract (the “**Contract**”) was entered into between the Company and Mr. Wang on 10 May 2024 for a period of three years. Pursuant to the Contract, Mr. Wang will not receive any director’s fee as an executive director of the Company. The remuneration for Mr. Wang as the chief executive officer of the Company is yet to be determined and the Company will announce such remuneration as soon as possible and no later than the poll results announcement of the forthcoming annual general meeting of the Company.

As at the date of this announcement, Mr. Wang does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, save as disclosed above, Mr. Wang has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Mr. Wang does not have any relationship with any director, senior management or substantial or controlling Shareholder(s) (as defined in the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) nor does he hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Mr. Wang has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

The Board would like to extend its warmest welcome to Mr. Wang for joining the Board.

RE-DESIGNATION OF ACTING CHIEF EXECUTIVE OFFICER

The Board further announces that, due to the appointment of Mr. Wang as the chief executive officer of the Company, Mr. Chen Fei (“**Mr. Chen**”), currently an executive director, the acting chief executive officer and the executive deputy general manager of the Company, will no longer act as the acting chief executive officer of the Company with effect from 10 May 2024 and will remain as an executive director and the executive deputy general manager of the Company.

Mr. Chen has confirmed that he has no disagreement with the Board, and there are no other matters in relation to being no longer act as the acting chief executive officer of the Company that need to be brought to the attention of the Shareholders or the Stock Exchange.

** For identification purposes only*

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Gu Hai Ou
Chairman

Hong Kong, 10 May 2024

As at the date of this announcement, the composition of the Board is as follows:

Executive Directors:

Mr. Gu Hai Ou (*Chairman*)
Mr. Wang Chi
Mr. Chen Fei

Independent Non-executive Directors:

Mr. Tsang Yok Sing, Jasper
Mr. Xu Hong Xi
Mr. Chan Ngai Chi

Non-executive Director:

Ms. Feng Li